As of June 3, 2025, Johnson & Johnson (JNJ) reports a Forward P/E of 14.50.
Forward P/E gauges the price investors pay for each dollar of anticipated earnings, offering insight into a stock's future valuation.
Comparing Johnson & Johnson's Forward P/E to Peers
To better understand Johnson & Johnson's position, it's useful to compare its Forward P/E against industry peers. Below are selected comparisons:
| Company | Forward P/E |
|---|---|
| Johnson & Johnson (JNJ) | 14.50 |
| Catalent Inc (CTLT) | 55.81 |
| Corcept Therapeutics Inc (CORT) | 50.52 |
| Eli Lilly and Co (LLY) | 33.87 |
| Zoetis Inc (ZTS) | 26.44 |
| Horizon Therapeutics PLC (HZNP) | 25.39 |
Compared to its competitors, Johnson & Johnson's Forward P/E is about average compared to peers, indicating growth expectations in line with industry peers.